• Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter
    You are here: Home > Pharmacy News | Health Articles/Tips > AstraZeneca > February 08, 2011

      AstraZeneca, Taj Pharma launch Gemcitabine HCI for Injection in US

      Posted Atdrugdiscovery.pharmaceutical-business-review.com

      AstraZeneca Pharmaceuticals and Taj Pharmaceuticals, an India-based manufacturer of generic drugs as well as specialty pharmaceuticals and active pharmaceutical ingredients, have commercially launched Gemcitabine HCI for Injection in 200 mg and 1 g single dose vials in the US.

      Gemcitabine HCI for Injection, the generic version of Gemcitabine HCI, was launched pursuant to a commercialization, manufacture and supply agreement signed by AstraZeneca and Taj Pharmaceuticals, indiacompanynews.com reported.

      As per the agreement, AstraZeneca will manufacture Gemcitabine HCI for Injection and will receive a license to market the product within the India-based firm's 180-day exclusivity.

      Taj Pharma will get a royalty during the manufacturing period.

      Indiacompanynews.com has quoted Taj Pharmaceuticals Generics senior vice president Ajay Sodhi sa saying that the agreement allows them to accelerate the availability of the important generic product Gemcitabine HCI.

      Feb 08, 2011


      Share this Article!

    Back to top^